Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, March 22 '25)

Image
By G.M.

 


    Ann Intern Med


  1. Correction: Anticoagulation Among Patients Hospitalized for COVID-19.
    Ann Intern Med. 2025 Mar 18. doi: 10.7326/ANNALS-25-00916.
    PubMed        


    Antiviral Res

  2. SAFIRIYU AA, Hussain A, Dewangan N, Kasle G, et al
    The fusion peptide of the spike protein S2 domain may be a mimetic analog of beta-coronaviruses and serve as a novel virus-host membrane fusion inhibitor.
    Antiviral Res. 2025 Mar 16:106144. doi: 10.1016/j.antiviral.2025.106144.
    PubMed         Abstract available

  3. XU M, Zhang Z, Sun Y, Mai H, et al
    Corrigendum to "IgA class switching enhances neutralizing potency against SARS-CoV-2 by increased antibody hinge flexibility" [Antiv. Res. (2025) 106082].
    Antiviral Res. 2025 Mar 20:106146. doi: 10.1016/j.antiviral.2025.106146.
    PubMed        


    Graefes Arch Clin Exp Ophthalmol

  4. ZUREIK A, Couturier A, Delcourt C
    Evolution of ophthalmological care in adult with diabetes in France between 2010 and 2022: a nationwide study.
    Graefes Arch Clin Exp Ophthalmol. 2025 Mar 17. doi: 10.1007/s00417-025-06793.
    PubMed         Abstract available


    Int J Infect Dis

  5. LASTRUCCI V, Pacifici M, Puglia M, Alderotti G, et al
    Recent trends in hospitalizations for Respiratory Syncytial Virus after the COVID-19 pandemic and before routine immunization: seasonality and severity updates from the 2023/2024 season in Tuscany, Italy.
    Int J Infect Dis. 2025 Mar 13:107879. doi: 10.1016/j.ijid.2025.107879.
    PubMed         Abstract available


    Intensive Care Med

  6. CHEN B, Li S
    Optimizing non-intubated respiratory support in COVID-19: evaluating the impact of bundle of care strategy on awake prone positioning tolerance.
    Intensive Care Med. 2025 Mar 17. doi: 10.1007/s00134-025-07860.
    PubMed        


    Invest Radiol

  7. SONG J, Hwang EJ, Yoon SH, Park CM, et al
    Emerging Trends and Innovations in Radiologic Diagnosis of Thoracic Diseases.
    Invest Radiol. 2025 Mar 20. doi: 10.1097/RLI.0000000000001179.
    PubMed         Abstract available


    J Infect

  8. PEREZ CM, Ruiz-Rius S, Ramirez-Morros A, Vidal M, et al
    Post-vaccination IgG4 and IgG2 class switch associates with increased risk of SARS-CoV-2 infections.
    J Infect. 2025 Mar 18:106473. doi: 10.1016/j.jinf.2025.106473.
    PubMed         Abstract available


    J Med Virol

  9. BOTELLO-MARABOTTO M, Tarraso J, Mulet A, Presa-Fernandez L, et al
    Metabolomic Biomarkers of Pulmonary Fibrosis in COVID-19 Patients One Year After Hospital Discharge.
    J Med Virol. 2025;97:e70289.
    PubMed         Abstract available

  10. VENTUROLI S, Bertoldi A, Manaresi E, Lazzarotto T, et al
    Epidemiology of Parvovirus B19 Infection In an Italian Metropolitan Area, 2012-2024: COVID-19 Pre-Pandemic, Pandemic and Post-Pandemic Trends.
    J Med Virol. 2025;97:e70296.
    PubMed         Abstract available

  11. FOURGEAUD J, Turlure P, Dupont M, Veyrenche N, et al
    Remdesivir for the Treatment of Human Coronavirus OC43 Encephalitis.
    J Med Virol. 2025;97:e70314.
    PubMed         Abstract available

  12. AMEGASHIE EA, Kwayisi-Darkwah CK, Adusei-Poku M, Sikeola RO, et al
    Lipid Peroxidation and Glutathione Levels Among People Living With HIV Co-infected With Human Coronaviruses in Ghana.
    J Med Virol. 2025;97:e70301.
    PubMed         Abstract available


    J Virol

  13. ZHONG Q, Qi J, Su N, Li Z, et al
    In vivo investigation of PEDV transmission via nasal infection: mechanisms of CD4(+) T-cell-mediated intestinal infection.
    J Virol. 2025 Mar 17:e0176124. doi: 10.1128/jvi.01761.
    PubMed         Abstract available

  14. SIMS A, Weir DJ, Cole SJ, Hutchinson E, et al
    SARS-CoV-2 cellular coinfection is limited by superinfection exclusion.
    J Virol. 2025 Mar 21:e0207724. doi: 10.1128/jvi.02077.
    PubMed         Abstract available

  15. BEAVIS AC, Li Z, Briggs K, Gingerich MC, et al
    Efficacy of parainfluenza virus 5 (PIV5)-vectored intranasal COVID-19 vaccine as a single dose primer and booster against SARS-CoV-2 variants.
    J Virol. 2025 Mar 21:e0198924. doi: 10.1128/jvi.01989.
    PubMed         Abstract available

  16. BEAVIS AC, Xiao P, Gingerich MC, Briggs K, et al
    A parainfluenza virus 5 (PIV5)-vectored intranasal SARS-CoV-2 vaccine (CVXGA1) elicits protective and long-lasting immunity in nonhuman primates.
    J Virol. 2025 Mar 21:e0199024. doi: 10.1128/jvi.01990.
    PubMed         Abstract available


    Lancet Infect Dis

  17. RAMOS B, Vadlamudi NK, Han C, Sadarangani M, et al
    Future immunisation strategies to prevent Streptococcus pneumoniae infections in children and adults.
    Lancet Infect Dis. 2025 Mar 17:S1473-3099(24)00740.
    PubMed         Abstract available

  18. HASLAM E
    Lessons from the COVID-19 pandemic.
    Lancet Infect Dis. 2025 Mar 13:S1473-3099(25)00177.
    PubMed        


    Nature

  19. MERKENSCHLAGER J, Pyo AGT, Silva Santos GS, Schaefer-Babajew D, et al
    Regulated somatic hypermutation enhances antibody affinity maturation.
    Nature. 2025 Mar 19. doi: 10.1038/s41586-025-08728.
    PubMed         Abstract available


    Travel Med Infect Dis

  20. RODRIGUEZ-MORALES AJ, Puerta-Arias MC, Husni R, Montenegro-Idrogo JJ, et al
    Infectious Diseases Prevention and Vaccination in migrants in Latin America: The challenges of transit through the treacherous Darien Gap, Panama.
    Travel Med Infect Dis. 2025 Mar 18:102839. doi: 10.1016/j.tmaid.2025.102839.
    PubMed        

  21. SRIVASTAVA S, Sharma D, Sridhar SB, Kumar S, et al
    HKU5-CoV-2: A silent threat looming in bats.
    Travel Med Infect Dis. 2025;65:102838.
    PubMed        
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »